Allergic Rhinitis Market to Register Incremental Growth During the Forecast Period 2030, Asserts DelveInsight | Key Companies -EMS, Bayer, Inmunotek, Allergy Therapeutics, ALK-Abello, and Others

 Breaking News
  • No posts were found

Allergic Rhinitis Market to Register Incremental Growth During the Forecast Period 2030, Asserts DelveInsight | Key Companies -EMS, Bayer, Inmunotek, Allergy Therapeutics, ALK-Abello, and Others

December 14
22:34 2021
Allergic Rhinitis Market to Register Incremental Growth During the Forecast Period 2030, Asserts DelveInsight | Key Companies -EMS, Bayer, Inmunotek, Allergy Therapeutics, ALK-Abello, and Others
Delveinsight Business Research LLP
DelveInsight’s “Allergic Rhinitis Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Allergic Rhinitis Market Size and Share in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Allergic Rhinitis market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2017 to 2030. It evaluates the current treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Allergic Rhinitis Market

Allergic Rhinitis: An Overview

Allergic Rhinitis (AR), also known as hay fever, is a type of inflammation in the nose that occurs when the immune system overreacts to allergens in the air. It is usually a long-standing condition that often goes undetected in the primary-care setting. The classic symptoms of the disorder are nasal congestion, nasal itch, rhinorrhea, and sneezing.

In some cases, Allergic Rhinitis also leads to some complications such as nasal polyps, sinusitis, and middle ear infections. These problems can often be treated with medication, although surgery is sometimes needed in severe or long-term cases.

The prevalence of AR increased from the 1990s to the early years of the first decade of the twenty-first century in many low and middle-income countries (LMICs) but decreased or had little change in western Europe.

Allergic Rhinitis Market Key Facts

  • As per the study conducted by Akhouri et al. 2021, “the prevalence of Allergic Rhinitis in the United States based on physician diagnosis is approximately 15%; however, the prevalence is estimated to be as high as 30% based on patients with nasal symptoms”.

  • As per the study conducted by Jean Bousquet et al. 2020, Allergic Rhinitis often begins early in life, with a prevalence of more than 5% at 3 years of age.

  • It is observed that Allergic Rhinitis is slightly more common in males in childhood than in females. From the age of fifteen onwards, females are affected more as compared to males.

  • As per the Asthma and Allergy Foundation of America, Allergic Rhinitis, often called hay fever. It affects 6.1 million of the children population and 20 million of the adult population in the United States. 

Allergic Rhinitis Market 

The Allergic Rhinitis Market is expected to increase during the forecast period owing to the higher prevalence of the disease, increasing respiratory disorders, and the expected launch of the pipeline therapies.

The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Allergic Rhinitis market size and share by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology. 

The report gives a thorough detail of the Allergic Rhinitis market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Get the PDF Sample of the Report:- Allergic Rhinitis Therapeutics Market

Allergic Rhinitis Epidemiology

The epidemiology section covers insights about the historical and current Allergic Rhinitis patient pool and forecasted trends for every seven major countries from 2017 to 2030. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Allergic Rhinitis Epidemiology Segmentation

  • Prevalent cases of Allergic Rhinitis

  • Gender-Specific Prevalent Cases of Allergic Rhinitis

  • Age-Specific Prevalent Cases of Allergic Rhinitis

  • Diagnosed and Treatable Cases of Allergic Rhinitis

Allergic Rhinitis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Allergic Rhinitis market or expected to get launched in the market during the study period. The analysis covers the Allergic Rhinitis market uptake by drugs; patient uptake by therapies; and sales of each drug. 

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Allergic Rhinitis Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.

Allergic Rhinitis Therapeutics Analysis

The dynamics of the Allergic Rhinitis market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, incremental healthcare spending across the world, and also the expected launch of emerging therapies

Some of the key companies in the Allergic Rhinitis Market include:

  • EMS

  • Bayer

  • Inmunotek S.L

  • Allergy Therapeutics

  • ALK-Abello A/S

  • Regeneron Pharmaceuticals

And several others

Allergic Rhinitis Therapies covered in the report include:

  • Magnólia Nasal Gel

  • Anti-Bet v 1

  • HDM SLIT-tablet

  • Azelastine hydrochloride (BAYR9258)

  • MM09-SIT-023

  • PQ Grass 27600 SU

  • GRASTEK

And many more

Get More Detailed Insights into the Emerging Therapies & Key Companies @  https://www.delveinsight.com/sample-request/allergic-rhinitis-market

Table of Content

1. Key Insights

2. Executive Summary 

3. Allergic Rhinitis Competitive Intelligence Analysis

4. Allergic Rhinitis Market Overview at a Glance

5. Allergic Rhinitis Disease Background and Overview

6. Allergic Rhinitis Patient Journey

7. Allergic Rhinitis Epidemiology and Patient Population

8. Allergic Rhinitis Treatment Algorithm, Current Treatment, and Medical Practices

9. Allergic Rhinitis Unmet Needs

10. Key Endpoints of Allergic Rhinitis Treatment

11. Allergic Rhinitis Marketed Products

12. Allergic Rhinitis Emerging Therapies

13. Allergic Rhinitis Seven Major Market Analysis

14. Attribute Analysis

15. Allergic Rhinitis Market Outlook (7 major markets)

16. Allergic Rhinitis Access and Reimbursement Overview

17. KOL Views on the Allergic Rhinitis Market.

18. Allergic Rhinitis Market Drivers

19. Allergic Rhinitis Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The table of contents is not exhaustive; the final content may vary. 

Request Sample Report here:- https://www.delveinsight.com/sample-request/allergic-rhinitis-market

Latest Reports By DelveInsight

Bevacizumab Biosimilars

DelveInsight’s, “Bevacizumab Biosimilar Insight, 2020,” report provides comprehensive insights about 40+ companies and 40+ marketed and pipeline drugs in the Bevacizumab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Related Articles

Calendar

January 2022
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
31  

Categories